EHP is committed to developing novel therapies focused initially on the treatment of four autoimmune and neurodegenerative diseases with unmet medical needs. We have the following clinical trials underway. For eligibility criteria and additional study details, visit www.ClinicalTrials.gov.

Emerald Health Pharmaceuticals’ Clinical Programs

Disease Study Phase Trial Objective Enrollment Status
Systemic Sclerosis

 

 

 

Phase IIa

More Information

 

 

EHP-101

Double-blind, randomized, intracohort placebo-controlled, multicenter study.

To evaluate the safety, tolerability, and preliminary efficacy of EHP-101 in patients with diffuse cutaneous systemic sclerosis.

 

 

Active.

Enrolling in the United States, Australia and New Zealand.

 

Multiple Sclerosis Initiating Phase II EHP-101

Open label study.

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of EHP-101 in patients with relapsing forms of multiple sclerosis. Enrollment scheduled to begin end of 2021.